Clinical trials: Immunosuppression
Kidney Failure
Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function
Tacrolimus is the standard immunosuppressive drug used to prevent organ rejection post liver transplant. One side effect of Tacrolimus is nephrotoxicity. Everolimus does not have the nephrotoxicity side effects of Tacrolimus.
- Trial name
- NCT04258423
- Testing
- Tacrolimus, Everolimus
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Indiana University
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00049504
- Testing
- cyclophosphamide, fludarabine phosphate, tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Renal Transplant Rejection, Kidney Transplant Failure and Rejection
Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation
This is a one year, prospective, randomized, open-label trial examining once versus twice daily tacrolimus dosing regimen using two preparations, extended-release Tacrolimus (Envarsus XR) versus twice daily Tacrolimus (Prograf).
- Trial name
- NCT03511560
- Testing
- Tacrolimus Extended Release Oral Tablet, Tacrolimus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Aplastic Anemia, Neutropenia
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
Background: Severe aplastic anemia (SAA) can lead to problems with bone marrow health and result in low blood cell counts, which require frequent transfusions.
- Conditions
- Aplastic Anemia, Neutropenia, Pancytopenia, Severe Aplastic Anemia
- Trial name
- NCT01187017
- Testing
- Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Kidney Failure, Chronic, Kidney Transplantation
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
The purpose of this study is to evaluate the safety of alemtuzumab after kidney transplantation as part of a multitherapy regimen to prevent kidney graft loss and death and to avoid steroids and chronic use of calcineurin…
- Conditions
- Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
- Trial name
- NCT00240994
- Testing
- Alemtuzumab, Tacrolimus, Mycophenolate mofetil
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Transplantation Infection
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
The purpose of this study was to allow the continuation of everolimus treatment in patients who have completed the core study (NCT00170885) and to collect long-term safety, tolerability, and efficacy data in a group of patients…
- Trial name
- EVEREST (NCT01276457)
- Testing
- Everolimus 0.25 and 0.75 mg tablets, Cyclosporine very low dose (150-300 ng/mL) microemulsion, Cyclosporine low dose (350-500 ng/mL) microemulsion
- Volunteers
- 223 people
- Sponsor
- Novartis Pharmaceuticals
Primary Focal Segmental Glomerulosclerosis
Obinutuzumab in Primary FSGS
The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.
- Trial name
- NCT04983888
- Testing
- Obinutuzumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Asses Immunosuppression Modulation on Renal Recovery Post LT
Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
This is a study to help understand how well new combinations of immunosuppressive medications (medications that weaken your immune system to prevent your body from rejecting the transplanted liver) work compared to standard…
- Trial name
- NCT04104438
- Testing
- Basiliximab 20 MG
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Fady M Kaldas, M.D., F.A.C.S.
Kidney Transplantation
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
This is a study that will follow transplant patients from Study A3921030 to monitor for long term safety, tolerability and efficacy for 5 additional years, except in Portugal where the study will follow transplant patients…
- Trial name
- NCT00658359
- Testing
- Cyclosporine, CP-690,550
- Where
- 65 sites in United States, Australia and 13 more
- Volunteers
- 178 people
- Sponsor
- Pfizer
Liver Disease, Liver Transplantation
Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
Alemtuzumab is a man-made antibody used to treat certain blood disorders. Tacrolimus is a drug used to decrease immune system activity in people who have received organ transplants so that the new organ will not be rejected.
- Trial name
- TILT (NCT00105235)
- Testing
- Alemtuzumab, Cyclosporine, Mycophenolate mofetil
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Solid Organ Transplant Recipients, Autoimmune Diseases
Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies
DESIGN Observational epidemiological study AIMS - To determine: 1. The proportion of immunosuppressed people who have detectable SARS-CoV-2 antibodies following a primary vaccine course (3 doses), and the demographic, disease…
- Conditions
- Solid Organ Transplant Recipients, Autoimmune Diseases, Haematological Malignancies
- Trial name
- MELODY (NCT05148806)
- Testing
- self-administered lateral flow assays
- Where
- 4 sites in United Kingdom
- Volunteers
- 28,411 people
- Sponsor
- Imperial College London
Kidney Transplant Immunosuppression
Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
The purpose of the study is to identify kidney transplant patients that can be transitioned from multi-drug immunosuppression therapy to Belatacept monotherapy, using cell free DNA and gene expression as markers of immune…
- Trial name
- NCT04786067
- Testing
- Belatacept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Texas Southwestern Medical Center
Kidney Transplantation
Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients
The study will evaluate kidney graft function in maintenance renal transplant patients.
- Trial name
- NCT00434590
- Testing
- Enteric coated mycophenolate sodium (Myfortic®)
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Type 1 Diabetes
Pancreatic Islet Cell Transplantation
The purpose of this study is to assess a novel approach to immunosuppression in allogenic pancreatic islet cell transplant recipients.
- Trial name
- NCT00214786
- Testing
- Islet cell transplantation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Baylor Research Institute
Liver Carcinoma
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.
- Trial name
- NCT00328770
- Testing
- Sirolimus
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University of Alberta
Kidney Diseases
Study of ISA247 (Voclosporin) in De Novo Renal Transplantation
This study will see if voclosporin is safe and effective in preventing kidney transplant rejection.
- Trial name
- PROMISE (NCT00270634)
- Testing
- Voclosporin, tacrolimus
- Where
- 45 sites in United States, Canada
- Volunteers
- 334 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Lung Transplant Rejection, Antibody-mediated Rejection
Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation
This is a pilot randomized controlled trial examining the feasibility of conducting a large scale randomized controlled trial of belatacept-based immunosuppression in lung transplantation.
- Trial name
- NCT03388008
- Testing
- Belatacept, Tacrolimus, ATG
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Stem Cell Transplant, Adherence, Medication
BMT4me: Post-HSCT Medication Adherence mHealth App
This is a mixed methods, prospective longitudinal pilot RCT to evaluate the 1) acceptability of a newly developed mHealth app (BMT4me), 2) the feasibility of enrolling and retaining caregivers of children in the acute phase…
- Conditions
- Stem Cell Transplant, Adherence, Medication, Digital Health
- Trial name
- Bmt4me 2 (NCT05515497)
- Testing
- BMT4me 2.0 app
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Micah Skeens
Severe Aplastic Anemia, Aplastic Anemia
NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
Our primary objective is to determine if it is feasible for previously untreated severe aplastic anemia (SAA) patients to be transplanted using non-myeloablative conditioning and post transplantation cyclophosphamide.
- Conditions
- Severe Aplastic Anemia, Aplastic Anemia, Bone Marrow Failure, Immunosuppression
- Trial name
- NCT02833805
- Testing
- Thymoglobulin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Kidney Transplant Rejection, Immunosuppression
Immune Monitoring to Facilitate Belatacept Monotherapy
To determine the utility of novel blood-based immune monitoring tools (Allosure and Trugraf) to facilitate belatacept monotherapy.
- Trial name
- NCT04177095
- Testing
- Allosure, Immunosuppression reduction, Trugraf
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital